1. Home
  2. PGP vs CALC Comparison

PGP vs CALC Comparison

Compare PGP & CALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pimco Global StocksPlus & Income Fund of Beneficial Interest

PGP

Pimco Global StocksPlus & Income Fund of Beneficial Interest

HOLD

Current Price

$9.03

Market Cap

102.9M

Sector

Finance

ML Signal

HOLD

Logo CalciMedica Inc.

CALC

CalciMedica Inc.

HOLD

Current Price

$6.02

Market Cap

88.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PGP
CALC
Founded
2003
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Finance Companies
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
102.9M
88.3M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
PGP
CALC
Price
$9.03
$6.02
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$16.00
AVG Volume (30 Days)
39.8K
93.6K
Earning Date
01-01-0001
11-12-2025
Dividend Yield
10.84%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.83
$1.42
52 Week High
$7.81
$7.20

Technical Indicators

Market Signals
Indicator
PGP
CALC
Relative Strength Index (RSI) 65.99 68.87
Support Level $8.52 $5.90
Resistance Level $8.91 $6.40
Average True Range (ATR) 0.11 0.59
MACD 0.01 0.13
Stochastic Oscillator 89.62 64.63

Price Performance

Historical Comparison
PGP
CALC

About PGP Pimco Global StocksPlus & Income Fund of Beneficial Interest

PIMCO Global Stocksplus & Income Fund is a closed-end management investment company. The objective of the fund is to seek a total return comprised of current income, current gains, and long-term capital appreciation. The fund invests a majority of the fund's net assets in a combination of securities and instruments that provide exposure to stocks and or produce income.

About CALC CalciMedica Inc.

CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys.

Share on Social Networks: